Cingulate Receives $4.3 Million PDUFA Fee Waiver for ADHD Treatment, CTx-1301
Cingulate announced today that it has received a fiscal year 2025 Prescription Drug User Fee Act (PDUFA) fee waiver from the US Food and Drug Administration (FDA) for its new drug application (NDA) for dexmethylphenidate HCI (CTx-1301) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older.1
Other Articles in this Edition
Breaking Down Treatment Barriers for Girls and Women With ADHD
ADHD Symptoms in Women Fluctuate With Hormonal Changes
ADHD can make your periods worse – here’s how to cope
The Financial Challenges of ADHD—And How To Overcome Them
People are Ditching ADHD Meds. Here’s What to Know About the Alternatives.
The Monster at the Dinner Table
No, Moms Are Not to Blame for ADHD
My child is always losing and forgetting things. How can I help – without making it worse?
Pharmacies experiencing relief from ADHD medication shortage
Cingulate Receives $4.3 Million PDUFA Fee Waiver for ADHD Treatment, CTx-1301